Anti-GM1 antibodies were measured in 22 patients with the Guillain-Barre syndrome (GBS) and compared with anti-GM1 antibody activity in patients with other neurological or immunological diseases and in normal subjects. Four out of 22 patients with GBS had raised IgM, IgG, or IgA anti-GM, antibody activities. All four patients were tetraparetic with only minimal or no sensory deficit. Three ofthe patients had highly raised antibody activity and showed severe residual deficits, while of the remaining patients with GBS, only one remained severely affected. One patient had anti-GM1 antibodies specific for GM1, whereas the other three patients showed antibody activity with asialo-GM1 or GD1b. 
four patients were tetraparetic with only minimal or no sensory deficit. Three ofthe patients had highly raised antibody activity and showed severe residual deficits, while of the remaining patients with GBS, only one remained severely affected. One patient had anti-GM1 antibodies specific for GM1, whereas the other three patients showed antibody activity with asialo-GM1 or GD1b. The presence of anti-GM1 antibodies may define a subgroup of patients with GBS who have a poor prognosis. (table 2) ose in and may have been specific for the Gal(BlFor 3)GalNAc epitope. In case 3, however, the ibody antibodies were specific for GM1. The van den Berg, Marrink, Jager, Jong, Imhoff, Latov, Sadiq Table 2 Fine specificities and course of raised activities of IgM, IgG, and IgA antibodies to GM,, asialo-GM, (aGM,), and GD,b (in A U/l, -= not raised) Case 1  12  350  900  250  1800  2000  500  --30  170  40  12  700  900  300  --99  50  30  -240  250  30  --156   ---140  200  ---Case 2  3  1300  1480  950  130  270  250  --17  520  690  490  ------30  220  250  160  ------35  180  250  130  ------101  23  70 antibodies in case 4 also bound to GDlb but not to asialo-GM,.
The IgM, IgG, and IgA antibody activities to GM1, asialo-GM, and GDlb were highest at the onset ofthe disease and decreased with time ( antibodies. The illness in both patients was preceded by campylobacter enteritis.
We detected increased activity of anti-GM1
antibodies in four out of 22 patients with GBS. These patients predominantly had motor neuropathy with severe denervation and the three patients with th, highest activities remained severely disabled. The patient in case 3, however, also had markedly slowed motor nerve conduction velocities. in GBS might thereby provide clues to the identity of the T cell antigen. The study suggests that patients with acute GBS who have highly raised anti-GM, antibody activities constitute a subgroup with motor neuropathy predominantly and substan-tial axonal damage. Detection of anti-GM, antibodies in patients with GBS therefore may be of prognostic value. Further elucidation of the pathogenic role of these autoantibodies in GBS may help in developing more specific and effective treatment.
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